231 related items for PubMed ID: 12476589
1. [Effect of angiotensin II receptor antagonist (losartan) on renal function, serum potassium and blood pressure in patients with advanced renal failure: differences between patients with a serum creatinine (SCr) level higher than 3 mg/dl and those with a lower SCr level].
Nakayama M, Tanno Y, Otsuka Y, Takahashi H, Ikeda M, Katoh N, Yokoyama K, Yamamoto H, Tokutome G, Hosoya T.
Nihon Jinzo Gakkai Shi; 2002 Oct; 44(7):530-6. PubMed ID: 12476589
[Abstract] [Full Text] [Related]
2. Interim evidence of the renoprotective effect of the angiotensin II receptor antagonist losartan versus the calcium channel blocker amlodipine in patients with chronic kidney disease and hypertension: a report of the Japanese Losartan Therapy Intended for Global Renal Protection in Hypertensive Patients (JLIGHT) Study.
Iino Y, Hayashi M, Kawamura T, Shiigai T, Tomino Y, Yamada K, Kitajima T, Ideura T, Koyama A, Sugisaki T, Suzuki H, Umemura S, Kawaguchi Y, Uchida S, Kuwahara M, Yamazaki T, Japanese Lasartan Therapy Intended for the Global Renal Protection in Hypertensive Patients (JLIGHT) Study Investigators.
Clin Exp Nephrol; 2003 Sep; 7(3):221-30. PubMed ID: 14586719
[Abstract] [Full Text] [Related]
3. Add-on angiotensin II receptor blockade lowers urinary transforming growth factor-beta levels.
Agarwal R, Siva S, Dunn SR, Sharma K.
Am J Kidney Dis; 2002 Mar; 39(3):486-92. PubMed ID: 11877567
[Abstract] [Full Text] [Related]
4. [Successful use of angiotensin II receptor antagonist (losartan) in a patient with scleroderma renal crisis].
Hasegawa S, Iesato K, Tsukahara T, Yamamoto S, Kondou Y, Ogawa M, Ueda S.
Nihon Jinzo Gakkai Shi; 2000 Feb; 42(2):60-5. PubMed ID: 10771577
[Abstract] [Full Text] [Related]
5. Protective effect of an oral adsorbent on renal function in chronic renal failure: determinants of its efficacy in diabetic nephropathy.
Sanaka T, Akizawa T, Koide K, Koshikawa S.
Ther Apher Dial; 2004 Jun; 8(3):232-40. PubMed ID: 15154877
[Abstract] [Full Text] [Related]
6. Long-term effects of losartan on proteinuria and renal function in patients with renal amyloidosis.
Dilek K, Usta M, Ersoy A, Ozdemir B, Yavuz M, Güllülü M, Yurtkuran M.
Scand J Urol Nephrol; 2002 Jun; 36(6):443-6. PubMed ID: 12623509
[Abstract] [Full Text] [Related]
7. Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease.
Ruilope LM, Aldigier JC, Ponticelli C, Oddou-Stock P, Botteri F, Mann JF.
J Hypertens; 2000 Jan; 18(1):89-95. PubMed ID: 10678548
[Abstract] [Full Text] [Related]
8. The effect of a keto acid supplement on the course of chronic renal failure and nutritional parameters in predialysis patients and patients on regular hemodialysis therapy: the Hungarian Ketosteril Cohort Study.
Zakar G, Hungarian Ketosteril Cohort Study.
Wien Klin Wochenschr; 2001 Sep 17; 113(17-18):688-94. PubMed ID: 11603104
[Abstract] [Full Text] [Related]
9. Effect of angiotensin II type-1 receptor blockers on stable allograft kidneys: prospective randomized study.
Nouri-Majalan N, Ghafari A, Moghaddasi S.
Transplant Proc; 2009 Sep 17; 41(7):2832-4. PubMed ID: 19765449
[Abstract] [Full Text] [Related]
10. Proinflammatory effects of oxidative stress in chronic kidney disease: role of additional angiotensin II blockade.
Agarwal R.
Am J Physiol Renal Physiol; 2003 Apr 17; 284(4):F863-9. PubMed ID: 12505865
[Abstract] [Full Text] [Related]
11. [Can angiotensin-converting enzyme inhibitor be used in chronic kidney disease patients with serum creatinine level greater than 266 micromol/L?].
Zhang GH, Hou FF, Zhang X, Liu QF.
Zhonghua Nei Ke Za Zhi; 2005 Aug 17; 44(8):592-6. PubMed ID: 16194413
[Abstract] [Full Text] [Related]
12. Serum concentration of potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil.
Saito M, Takada M, Hirooka K, Isobe F, Yasumura Y.
J Clin Pharm Ther; 2005 Dec 17; 30(6):603-10. PubMed ID: 16336294
[Abstract] [Full Text] [Related]
13. Comparative effect of lisinopril and lacidipine on urinary albumin excretion in patients with type 11 diabetic nephropathy.
Salako BL, Finomo FO, Kadiri S, Arije A, Olatosin AO.
Afr J Med Med Sci; 2002 Mar 17; 31(1):53-7. PubMed ID: 12518931
[Abstract] [Full Text] [Related]
14. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].
Cases Amenós A, Goicoechea Diezhandiño M, de Alvaro Moreno F.
Nefrologia; 2008 Mar 17; 28 Suppl 3():39-48. PubMed ID: 19018737
[Abstract] [Full Text] [Related]
15. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study.
Bakris GL, Weir MR, Shanifar S, Zhang Z, Douglas J, van Dijk DJ, Brenner BM, RENAAL Study Group.
Arch Intern Med; 2003 Jul 14; 163(13):1555-65. PubMed ID: 12860578
[Abstract] [Full Text] [Related]
16. Prescriptions for angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and monitoring of serum creatinine and potassium in patients with chronic kidney disease.
Wang PT, Huang YB, Lin MY, Chuang PF, Hwang SJ.
Kaohsiung J Med Sci; 2012 Sep 14; 28(9):477-83. PubMed ID: 22974666
[Abstract] [Full Text] [Related]
17. Effect of erythropoietin on urinary liver-type fatty-acid-binding protein in patients with chronic renal failure and anemia.
Nakamura T, Sugaya T, Kawagoe Y, Suzuki T, Ueda Y, Koide H.
Am J Nephrol; 2006 Sep 14; 26(3):276-80. PubMed ID: 16772708
[Abstract] [Full Text] [Related]
18. Angiotensin receptor blocker reduces proteinuria independently of blood pressure in children already treated with Angiotensin-converting enzyme inhibitors.
Seeman T, Pohl M, Misselwitz J, John U.
Kidney Blood Press Res; 2009 Sep 14; 32(6):440-4. PubMed ID: 20016211
[Abstract] [Full Text] [Related]
19. Distinct time courses of renal protective action of angiotensin receptor antagonists and ACE inhibitors in chronic renal disease.
Matsuda H, Hayashi K, Saruta T.
J Hum Hypertens; 2003 Apr 14; 17(4):271-6. PubMed ID: 12692572
[Abstract] [Full Text] [Related]
20. "Point of no return (PNR)" in progressive IgA nephropathy: significance of blood pressure and proteinuria management up to PNR.
Komatsu H, Fujimoto S, Sato Y, Hara S, Yamada K, Morita S, Eto T.
J Nephrol; 2005 Apr 14; 18(6):690-5. PubMed ID: 16358226
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
